Osteoporosis International

, Volume 21, Issue 5, pp 837–846

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

  • D. L. Kendler
  • L. Bessette
  • C. D. Hill
  • D. T. Gold
  • R. Horne
  • S. F. Varon
  • J. Borenstein
  • H. Wang
  • H.-S. Man
  • R. B. Wagman
  • S. Siddhanti
  • D. Macarios
  • H. G. Bone
Original Article

Abstract

Summary

The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment that was administered less frequently, suggesting the acceptability of the 6-month injection for treatment of bone loss.

Introduction

The PSQ compares patient preference and satisfaction between a 6-month subcutaneous injection and a weekly oral tablet for treatment of bone loss.

Methods

Postmenopausal women with low bone mass who enrolled in two separate randomized phase 3 double-blind, double-dummy studies received a 6-month subcutaneous denosumab injection (60 mg) plus a weekly oral placebo or a weekly alendronate tablet (70 mg) plus a 6-month subcutaneous placebo injection. After 12 months, patients completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen.

Results

Most enrolled patients (1,583 out of 1,693; 93.5%) answered ≥1 item of the PSQ. Significantly more patients preferred and were more satisfied with the 6-month injection versus the weekly tablet (P < 0.001). More patients reported no bother with the 6-month injection (90%) than the weekly tablet (62%).

Conclusion

Patients preferred, were more satisfied, and less bothered with a 6-month injection regimen for osteoporosis.

Keywords

Injection Osteoporosis Preference Questionnaire Satisfaction Tablet 

Supplementary material

198_2009_1023_MOESM1_ESM.doc (44 kb)
Supplementary Table 1PSQ responses by language and country for the questions: “Which do you prefer?” and “With which frequency of administration have you been more satisfied?” (DOC 44 kb)

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  • D. L. Kendler
    • 1
  • L. Bessette
    • 2
  • C. D. Hill
    • 3
  • D. T. Gold
    • 4
  • R. Horne
    • 5
  • S. F. Varon
    • 6
    • 7
  • J. Borenstein
    • 7
  • H. Wang
    • 7
  • H.-S. Man
    • 8
  • R. B. Wagman
    • 9
    • 10
  • S. Siddhanti
    • 7
  • D. Macarios
    • 7
  • H. G. Bone
    • 11
  1. 1.Prohealth Clinical ResearchUniversity of British ColumbiaVancouverCanada
  2. 2.Le Centre Hospitalier Universitaire de QuébecPavillon CHULQuebec CityCanada
  3. 3.RTI Health SolutionsRTI InternationalResearch Triangle ParkUSA
  4. 4.Center for AgingDuke University Medical CenterDurhamUSA
  5. 5.Centre for Behavioral Medicine, The School of PharmacyUniversity of LondonLondonUK
  6. 6.AllerganIrvineUSA
  7. 7.Amgen Inc.Thousand OaksUSA
  8. 8.Amgen Inc.CambridgeUK
  9. 9.Amgen Inc.South San FranciscoUSA
  10. 10.Stanford University School of MedicineStanfordUSA
  11. 11.Michigan Bone and Mineral Clinic, P.C.DetroitUSA

Personalised recommendations